Diabetic dyslipidemia and residual risk in the era of LDL control
Dr. Aruna Pradhan describes the role of triglyceride lowering in reducing CV risk in patients with T2DM.
Video navigation menu
- Diabetes-related changes in lipid profile 01:30
- Residual CVD risk after treatment with statin +/- PCSK9 inhibitor in T2DM 02:15
- Should we target triglycerides to address residual triglyceride risk? 04:25
- How do triglycerides cause atherogenesis? 05:15
- Therapeutic potential of PPAR-α modulation in T2DM 09:02
This video was recorded on October 26, 2017 in Boston and is a shortened version of the presentation that Dr. Pradhan gave there during the educational program 'Advances in Lipid Management and Cardiovascular Risk Reduction: New Horizons for 2018'
Dr. Aruna Pradhan is Associate Physician at Brigham and Women's Hospital (BWH) and Assistant Professor of Medicine, Harvard Medical School (HMS).
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme. PACE-cme did not receive financial support for the production of this recording.